Stockholm - April 11, 2024 - Inify Laboratories, a unique laboratory service
provider within pathology and cancer diagnostics, presents its Annual Report for
the fiscal year ended December 31, 2023.

The annual report is attached to this press release and is also available on the
company's website: www.inify.com.

Printed copies of the report will be distributed upon request sent to e-mail:
ir@inify.com.

For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann
-charlotte.linderoth@inify.com or: ir@inify.com

###

About Inify Laboratories

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate. The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
from ContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed on Euronext Growth
Oslo under the ticker
INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.